医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer

2016年06月17日 PM06:44
このエントリーをはてなブックマークに追加


 

XIAMEN, China

Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx® ROS1 test successfully supported OxOnc Development LP (“OxOnc”) in the completion of a Phase 2 study of crizotinib (the “OxOnc Study”) in East Asian patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC). The OxOnc Study met its primary objective of demonstrating a high overall response rate for crizotinib. It enrolled 127 ROS1-positive patients in the People’s Republic of China (PRC), Japan, Taiwan and South Korea by using AmoyDx® ROS1 gene fusions test, and is the largest ROS1-positive NSCLC cohort reported to date. Results from the OxOnc Study were presented at the recent 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. (http://oxonc.com/pdfs/OxOncRelease020713.pdf). ROS1 gene rearrangements occur in about 2.4 percent of Asian patients with NSCLC. An estimated 1.5 million new cases of NSCLC are diagnosed worldwide each year.

“We expect NSCLC patients with ROS1 translocations to benefit significantly from the OxOnc Study results. AmoyDx aims to provide our customers with superior and innovative products and services to improve healthcare and patient well-being, and in particular, contribute to the development of new cancer therapies and precision medicine,” said Dr. Zheng, AmoyDx’s CEO and President.

“We are pleased to collaborate with AmoyDx, and appreciate the excellent performance of the ROS1 diagnostic test which was critical to the success of our study completion,” said Dr. Wenn Sun, OxOnc’s Managing Partner. In February 2013, OxOnc announced that it had entered into a co-development agreement with Pfizer to conduct the OxOnc Study. (http://oxonc.com/pdfs/OxOncRelease020713.pdf)

AmoyDx has obtained CE-mark for its ROS1 kit detecting 14 ROS1 gene fusions in Europe in November 2013 and received Chinese FDA (CFDA) approval in September 2014. This highly sensitive assay uses real-time PCR technology to analyze tumor messenger RNA from human tumor tissue or tumor cells and can derive results within 2.5 hours. For NSCLC precision medicine, AmoyDx also provides EGFR, KRAS, BRAF, ALK, ALK/ROS1, EGFR/ALK/ROS1 detection kits, which are both CE certified and CFDA approved.

About AmoyDx:

Amoy Diagnostic Co., Ltd. is an R&D based provider of state-of-the-art companion diagnostic products and services in the area of human precision oncology. Its customers include healthcare providers, pharmaceutical companies and academic institutions. The company has a rich portfolio of oncology molecular testing products which can be used for the detection of gene mutation/fusions of different cancer types including but not limited to lung cancer, colorectal cancer, breast cancer, cervical cancer and melanoma. AmoyDx is one of market leaders in the field of oncology diagnostics for precision medicines and its products have been widely used in more than 40 countries.
(www.amoydx.com)

View source version on businesswire.com: http://www.businesswire.com/news/home/20160617005218/en/

CONTACT

Amoy Diagnostics Co., Ltd.
Jiemin Luo, Ph.D., +86-592-680.6830
Fax:
+86-592-680.6839
zjb@amoydx.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果